Max Taubert results 7
· Newest (Page 1/1, per page 25)
Author: Max Taubert ×Clear All Filters
Search Results
Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteersNARA Subscribed
Purpose Currently, body weight-based dosing of rifampicin is recommended. But lately, fat-free mass (FFM) was reported to be superior to body weight (BW). The present evaluation aimed to assess the influence of body mass-related covariates on rifampicin’s pharmacokinetics (PK) parameters in more detail using non-linear mixed effects modeling (NLMEM). Methods Twenty-four healthy Caucasian volunteers were enrolled in a bioequiva...
Understanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktailNARA Subscribed
Purpose Adefovir (as dipivoxil) was selected as a probe drug in a previous transporter cocktail phenotyping study to assess renal organic anion transporter 1 (OAT1), with renal clearance (CL R ) as the primary parameter describing renal elimination. An approximately 20% higher systemic exposure of adefovir was observed when combined with other cocktail components (metformin, sitagliptin, pitavastatin, and digoxin) compared to...
A population pharmacokinetic model of remdesivir and its major metabolites based on published mean values from healthy subjectsNARA Subscribed
Remdesivir is a direct-acting anti-viral agent. It was originally evaluated against filoviruses. However, during the COVID-19 pandemic, it was investigated due to its anti-viral activities against (SARS-CoV-2) virus. Therefore remdesivir received conditional approval for treatment of patients with severe coronavirus disease. Yet, its pharmacokinetic properties are inadequately understood. This report describes the population p...
Previous1Next